Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down - Here's Why

Key Points

• Shares gapped down before Monday’s open from $15.8150 to $14.55 and last traded at $14.55 on just 120 shares, signaling a sharp move on very low volume.
• Ono beat quarterly expectations with $0.40 EPS vs $0.29 expected and revenue of $892.7M vs $727.6M, while reporting a net margin of 12.29% and ROE of 7.76%.
• The company has a market cap of $6.83B and a P/E of 16.35, solid liquidity (current ratio 3.02, quick ratio 2.56) and low leverage (debt/equity 0.10), and is known for its collaboration with Bristol-Myers Squibb on the checkpoint inhibitor Opdivo.

Ono Pharmaceutical Co. (OTCMKTS:OPHLF - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $15.8150, but opened at $14.55. Ono Pharmaceutical shares last traded at $14.55, with a volume of 120 shares changing hands.

Ono Pharmaceutical Price Performance

The business's fifty day moving average price is $15.46 and its 200-day moving average price is $13.32. The company has a market capitalization of $6.83 billion, a P/E ratio of 16.35 and a beta of 0.23. The company has a current ratio of 3.02, a quick ratio of 2.56 and a debt-to-equity ratio of 0.10.

Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) last released its earnings results on Monday, February 2nd. The company reported $0.40 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.11. Ono Pharmaceutical had a return on equity of 7.76% and a net margin of 12.29%.The business had revenue of $892.70 million for the quarter, compared to analysts' expectations of $727.58 million.

Ono Pharmaceutical Company Profile

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.